10/19/2005 5:13:16 PM
SLOUGH, U.K., April 13, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that it has entered into a licensing agreement for its lead product candidate, TransMID(TM), with PharmaEngine, Inc. (PEI) of Taiwan for the Chinese and South Korean markets.Under the terms of the agreement, Xenova will receive an upfront payment as well as milestone payments and significant royalties on potential future sales. Xenova also retains manufacturing rights and will be the exclusive supplier of TransMID(TM) to PEI. PEI receives exclusive rights to develop, market and sell TransMID(TM) in both the People's Republic of China and in the Republic of South Korea following PEI sponsored registration trials in these countries.
comments powered by